Bill Haney, Dragonfly Therapeutics CEO (Photo by Dave Pedley/Getty Images for SXSW)
May 2, 2022 08:30 AM EDT
Deals
Bioregnum

Gilead joins a line­up of Big Phar­ma part­ners bet­ting big on TriN­KETs, with a $300M cash ante to get start­ed on a 5T4

John Carroll

Editor & Founder

Bill Haney’s Drag­on­fly Ther­a­peu­tics is mak­ing the vault be­tween biotech start­up and the next big lev­el: adding clin­i­cal-stage com­pounds to its own fledg­ling pipeline while …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

Trump’s sci­ence crack­down hits rare dis­ease re­search: ‘We need to sit down with Elon Musk’

Ex­clu­sive: In­fec­tious dis­ease doc­tors con­sid­er 'mi­ni-ACIP' if RFK erodes CDC vac­cine pan­el

At least sev­en drug­mak­ers say they will par­tic­i­pate in round two of IRA ne­go­ti­a­tions 

Lil­ly joins mol­e­c­u­lar glue field with Mag­net deal worth up to $1.25B

Paci­ra ab­sorbs GQ Bio for $32M; Lay­offs at BMS, Ei­sai and CRISPR Ther­a­peu­tics

sponsored

How AI can ad­dress on­go­ing chal­lenges in the life sci­ences in­dus­try

A service from the Financial Times